© 2021 MJH Life Sciences and Urology Times. All rights reserved.
© 2021 MJH Life Sciences™ and Urology Times. All rights reserved.
June 01, 2021
The guideline was initially published in 2013 and was last amended in 2017.
May 21, 2021
"Certainly, telemedicine is not a replacement for in-person encounters for all urologic conditions, but rather another tool in our armamentarium," writes Adele M. Caruso, DNP, CRNP, FAANP.
April 26, 2021
Overall survival was similar between patients selecting primary intervention or active surveillance.
April 21, 2021
Frontline immune checkpoint inhibitor therapy may improve overall survival in this setting.
Around the Practice: High-Risk Renal Cell Carcinoma
April 19, 2021
"Brain imaging is routinely obtained for kidney cancer patients with symptoms that suggest CNS metastases, but none of the patients with brain metastases included here were symptomatic," said Martin H. Voss, MD.
April 12, 2021
Substudy 03B is enrolling patients with disease progression after treatment with PD-1/PD-L1 inhibitors and VEGF-tyrosine kinase inhibitors.
April 08, 2021
The phase 3 KEYNOTE-564 trial remains ongoing to evaluate the key secondary end point of overall survival.
April 07, 2021
This recommendation is key for urologists to be aware of, in particular, because of the role of the multidisciplinary approach to renal cell carcinoma care, according to Eric Jonasch, MD.
April 01, 2021
Primo Lara, Jr, MD, highlights the multitude of available treatments in frontline renal cell carcinoma, and the need for individualized, multidisciplinary treatment in this setting.